It is a recognized fact that the developing world has been used by the World Health Organization as a vaccine laboratory for decades. This has been proven in data and vaccine studies dating back as far as the 1970s.
With this in mind, we must ask ourselves, is it right to use these vulnerable children in vaccine experiments? I urge you to read the following examples before you come to any conclusions.
Group A Streptococcus (GAS) Unlicensed Vaccine Tested In Africa and Asia
In a report written for the World Health Organization (WHO), titled Status of Vaccine Research and Development of Vaccines for Streptococcus pyogenes Prepared for WHO PD-VAC , the authors state:
Concerns regarding vaccine safety are based upon a theoretical risk of autoimmune reactions in vaccinees leading to the development of ARF. One small study of a crude M protein vaccine suggested that there may be an increased risk of ARF in vaccine recipients; however, there are a number of concerns about the design of this trial that make it difficult to interpret, and autoimmune reactions have not been observed in the other human GAS vaccine trials involving thousands of study subjects.
Understanding of human GAS immunity remains incomplete. More information is needed regarding immune protection against GAS skin infection, the role of T-cell immunity and the relative contributions of non-M type-specific antigens (common antigens) in inducing protective immunity. Better epidemiologic data are also required, for assessing burden of disease to strengthen the case for GAS vaccine development and for assessing vaccine coverage more systematically with high quality, standardized molecular typing studies in more countries, particularly in Africa and Asia.